There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Russell Alan J, the Chief Scientific Officer of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), executed a series of stock transactions recently, as detailed in a recent SEC filing. On February 5 and 6, ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today. The company’s ...

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - - Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Edgewise ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment with a market capitalization of $2.6 billion, today announced significant ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen's other long-term stock picks. Andreas Halvorsen is a prominent ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...